287 related articles for article (PubMed ID: 23676646)
1. [Progression of bone marrow fibrosis with reticulin and collagen hyperplasia during treatment with the thrombopoietin receptor agonist romiplostim in a patient with immune thrombocytopenia].
Kirito K; Komatsu N
Rinsho Ketsueki; 2013 Mar; 54(3):295-9. PubMed ID: 23676646
[TBL] [Abstract][Full Text] [Related]
2. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia.
Janssens A; Rodeghiero F; Anderson D; Chong BH; Boda Z; Pabinger I; Červinek L; Terrell DR; Wang X; Franklin J
Ann Hematol; 2016 Jun; 95(7):1077-87. PubMed ID: 27130310
[TBL] [Abstract][Full Text] [Related]
3. Romiplostim-related myelofibrosis in refractory primary immune thrombocytopenia: A Case report.
Kim HY; Park SW; Kim JH; Kang JH; Lee WS; Song HN
Medicine (Baltimore); 2019 Jun; 98(25):e15882. PubMed ID: 31232923
[TBL] [Abstract][Full Text] [Related]
4. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.
Ghanima W; Junker P; Hasselbalch HC; Boiocchi L; Geyer JT; Feng X; Gudbrandsdottir S; Orazi A; Bussel JB
Br J Haematol; 2011 Oct; 155(2):248-55. PubMed ID: 21902682
[TBL] [Abstract][Full Text] [Related]
5. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.
Newland A; Godeau B; Priego V; Viallard JF; López Fernández MF; Orejudos A; Eisen M
Br J Haematol; 2016 Jan; 172(2):262-73. PubMed ID: 26537623
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.
Rodeghiero F; Stasi R; Giagounidis A; Viallard JF; Godeau B; Pabinger I; Cines D; Liebman H; Wang X; Woodard P
Eur J Haematol; 2013 Nov; 91(5):423-36. PubMed ID: 23927437
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim.
Kuter DJ; Mufti GJ; Bain BJ; Hasserjian RP; Davis W; Rutstein M
Blood; 2009 Oct; 114(18):3748-56. PubMed ID: 19671919
[TBL] [Abstract][Full Text] [Related]
8. Romiplostim.
Kuter DJ
Cancer Treat Res; 2011; 157():267-88. PubMed ID: 21052962
[TBL] [Abstract][Full Text] [Related]
9. Romiplostim in chronic immune thrombocytopenic purpura.
Cersosimo RJ
Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
[TBL] [Abstract][Full Text] [Related]
10. Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostim, a thrombopoietin receptor agonist.
LaMoreaux B; Barbar-Smiley F; Ardoin S; Madhoun H
Semin Arthritis Rheum; 2016 Feb; 45(4):e10-2. PubMed ID: 26329147
[TBL] [Abstract][Full Text] [Related]
11. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
Bussel JB; Hsieh L; Buchanan GR; Stine K; Kalpatthi R; Gnarra DJ; Ho RH; Nie K; Eisen M
Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874
[TBL] [Abstract][Full Text] [Related]
12. Reversible bone marrow reticulin fibrosis as a side effect of romiplostim therapy for the treatment of chronic refractory immune thrombocytopenia.
Leung T; Lokan J; Turner P; Smith C
Pathology; 2011 Aug; 43(5):520-2. PubMed ID: 21753725
[No Abstract] [Full Text] [Related]
13. Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim.
Cines DB; Gernsheimer T; Wasser J; Godeau B; Provan D; Lyons R; Altomare I; Wang X; Lopez A
Int J Hematol; 2015 Sep; 102(3):259-70. PubMed ID: 26201709
[TBL] [Abstract][Full Text] [Related]
14. Romiplostim: a review of its use in immune thrombocytopenia.
Keating GM
Drugs; 2012 Feb; 72(3):415-35. PubMed ID: 22316355
[TBL] [Abstract][Full Text] [Related]
15. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
16. Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim.
Al-Samkari H; Van Cott EM; Kuter DJ
Ann Hematol; 2019 Mar; 98(3):581-588. PubMed ID: 30446804
[TBL] [Abstract][Full Text] [Related]
17. Treatment of 5 dogs with immune-mediated thrombocytopenia using Romiplostim.
Kohn B; Bal G; Chirek A; Rehbein S; Salama A
BMC Vet Res; 2016 Jun; 12():96. PubMed ID: 27283401
[TBL] [Abstract][Full Text] [Related]
18. Use of romiplostim in a hemodialysis patient with primary immune thrombocytopenia.
Al-Jafar H; Giagounidis A; El-Rashaid K; Al-Ali M; Hakim AA
Ann Pharmacother; 2012 Nov; 46(11):e31. PubMed ID: 23115229
[TBL] [Abstract][Full Text] [Related]
19. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
[TBL] [Abstract][Full Text] [Related]
20. Highly fluctuating thrombocytopenia developing in a patient with immune thrombocytopenia (ITP) while administering romiplostim.
Shinohara K; Kambara N
Intern Med; 2012; 51(11):1399-401. PubMed ID: 22687850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]